Standard BioTools Inc. Available-for-sale Securities, Amortized Cost Basis
Standard BioTools Inc. (LAB) had Available-for-sale Securities, Amortized Cost Basis of $40.42 million as of 2018-06-30, per its 10-Q filed 2018-08-08.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-08-08
- 2018-06-30: Available-for-sale Securities, Amortized Cost Basis $40.42M.
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $47.25M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $63.14M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $62.37M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-06-30 | $40.42M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $47.25M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $63.14M 10-Q · filed 2018-08-08 |
| 2017-09-30 | $62.37M 10-Q · filed 2017-11-07 |
| 2017-06-30 | $42.03M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $50.28M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $59.43M 10-K · filed 2018-03-08 |
| 2016-09-30 | $71.23M 10-Q · filed 2016-11-09 |
| 2015-12-31 | $101.54M 10-K · filed 2017-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |